Show simple item record

dc.contributor.authorWilliams, Bryan
dc.contributor.authorMacDonald, Thomas M
dc.contributor.authorMorant, Steve
dc.contributor.authorWebb, David J
dc.contributor.authorSever, Peter
dc.contributor.authorMcInnes, Gordon
dc.contributor.authorFord, Ian
dc.contributor.authorCruickshank, J Kennedy
dc.contributor.authorCaulfield, Mark J
dc.contributor.authorSalsbury, Jackie
dc.contributor.authorMackenzie, Isla
dc.contributor.authorPadmanabhan, Sandosh
dc.contributor.authorBrown, Morris J
dc.contributor.authorBritish Hypertension Society's PATHWAY Studies Group
dc.date.accessioned2015-09-16T12:35:14Z
dc.date.available2015-09-16T12:35:14Z
dc.date.issued2015-11-21
dc.identifier.citationThe Lancet 2015, 386(10008): 2059–2068. doi:10.1016/S0140-6736(15)00257-3
dc.identifier.issn0140-6736
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/250603
dc.descriptionThis is the final version of the article. It first appeared from Elsevier via http://dx.doi.org/10.1016/S0140-6736(15)00257-3
dc.description.abstractBACKGROUND: Optimal drug treatment for patients with resistant hypertension is undefined. We aimed to test the hypotheses that resistant hypertension is most often caused by excessive sodium retention, and that spironolactone would therefore be superior to non-diuretic add-on drugs at lowering blood pressure. METHODS: In this double-blind, placebo-controlled, crossover trial, we enrolled patients aged 18-79 years with seated clinic systolic blood pressure 140 mm Hg or greater (or ≥135 mm Hg for patients with diabetes) and home systolic blood pressure (18 readings over 4 days) 130 mm Hg or greater, despite treatment for at least 3 months with maximally tolerated doses of three drugs, from 12 secondary and two primary care sites in the UK. Patients rotated, in a preassigned, randomised order, through 12 weeks of once daily treatment with each of spironolactone (25-50 mg), bisoprolol (5-10 mg), doxazosin modified release (4-8 mg), and placebo, in addition to their baseline blood pressure drugs. Random assignment was done via a central computer system. Investigators and patients were masked to the identity of drugs, and to their sequence allocation. The dose was doubled after 6 weeks of each cycle. The hierarchical primary endpoints were the difference in averaged home systolic blood pressure between spironolactone and placebo, followed (if significant) by the difference in home systolic blood pressure between spironolactone and the average of the other two active drugs, followed by the difference in home systolic blood pressure between spironolactone and each of the other two drugs. Analysis was by intention to treat. The trial is registered with EudraCT number 2008-007149-30, and ClinicalTrials.gov number, NCT02369081. FINDINGS: Between May 15, 2009, and July 8, 2014, we screened 436 patients, of whom 335 were randomly assigned. After 21 were excluded, 285 patients received spironolactone, 282 doxazosin, 285 bisoprolol, and 274 placebo; 230 patients completed all treatment cycles. The average reduction in home systolic blood pressure by spironolactone was superior to placebo (-8·70 mm Hg [95% CI -9·72 to -7·69]; p<0·0001), superior to the mean of the other two active treatments (doxazosin and bisoprolol; -4·26 [-5·13 to -3·38]; p<0·0001), and superior when compared with the individual treatments; versus doxazosin (-4·03 [-5·04 to -3·02]; p<0·0001) and versus bisoprolol (-4·48 [-5·50 to -3·46]; p<0·0001). Spironolactone was the most effective blood pressure-lowering treatment, throughout the distribution of baseline plasma renin; but its margin of superiority and likelihood of being the best drug for the individual patient were many-fold greater in the lower than higher ends of the distribution. All treatments were well tolerated. In six of the 285 patients who received spironolactone, serum potassium exceeded 6·0 mmol/L on one occasion. INTERPRETATION: Spironolactone was the most effective add-on drug for the treatment of resistant hypertension. The superiority of spironolactone supports a primary role of sodium retention in this condition. FUNDING: The British Heart Foundation and National Institute for Health Research.
dc.description.sponsorshipThe study was funded by a special project grant from the British Heart Foundation (number SP/08/002). Further funding was provided by the National Institute for Health Research (NIHR) Comprehensive Local Research Networks. BW, PS, MC, and MJB are NIHR Senior Investigators, and are supported by, respectively, the NIHR UCL/UCL Hospitals Biomedical Research Centre, the Biomedical Research Centre award to Imperial College Healthcare NHS Trust, the NIHR Cardiovascular Biomedical research Unit at St Bartholomew’s Hospital, London, and the NIHR Biomedical Research Centre award to Cambridge University Hospitals NHS Trust. Blinded medication was packed by Alan Wong and colleagues at the Royal Free Hospital pharmacy
dc.language.isoen
dc.publisherElsevier BV
dc.rightsAttribution 2.0 UK: England & Wales
dc.rights.urihttp://creativecommons.org/licenses/by/2.0/uk/
dc.titleSpironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
dc.typeArticle
dc.type.versionpublished version
prism.endingPage2068
prism.issueIdentifier10008
prism.publicationDate2015
prism.publicationNameLancet
prism.startingPage2059
prism.volume386
dc.rioxxterms.funderBHF
dc.rioxxterms.funderNIHR
dc.rioxxterms.projectidSP/08/002
pubs.declined2017-10-11T13:54:38.60+0100
rioxxterms.versionofrecord10.1016/S0140-6736(15)00257-3
dc.identifier.eissn1474-547X
pubs.funder-project-idBritish Heart Foundation (None)
pubs.funder-project-idBritish Heart Foundation (None)
pubs.funder-project-idBritish Heart Foundation (None)
pubs.funder-project-idBritish Heart Foundation (None)
pubs.funder-project-idBritish Heart Foundation (None)


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 2.0 UK: England & Wales
Except where otherwise noted, this item's licence is described as Attribution 2.0 UK: England & Wales